Smith & Nephew rating upgraded to “buy” — 5 things to know

Smith & Nephew was upgraded to a “buy” rating by equities research analysts at Goldman Sachs, according to a Dakota Financial News report.

Advertisement

Here are five things to know about the company’s stock:

 

•    Goldman Sachs upgraded Smith & Nephew from a “neutral” rating.
•    Smith & Nephew has a one-year low of $28.87 and a one-year high of $40.38.
•    The stock’s 50-day moving average is $35 and its 200-day moving average is $34.
•    The company has a market cap of $15.32 billion.
•    Currently, the stock has an average rating of “hold” and an average price target of $63.30.

More articles on devices:
10 things to know about the PRP market through 2020
Zimmer CEO sells stock in $150k transaction — 5 key notes
John Dahldorf becomes new Benvenue Medical CFO — 5 key notes

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.